Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words '2ND-LINE TREATMENT' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 53 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Tester, W; Mora, J
      Innovative treatments for advanced non-small cell lung cancer

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    2. Keating, GM; Goa, KL
      Management of advanced breast cancer - Defining the role of Anastrozole

      DISEASE MANAGEMENT & HEALTH OUTCOMES
    3. Buzdar, A; Howell, A
      Advances in aromatase inhibition: Clinical efficacy and tolerability in the treatment of breast cancer

      CLINICAL CANCER RESEARCH
    4. Robinson, BW; Shewach, DS
      Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breastcarcinoma cell lines

      CLINICAL CANCER RESEARCH
    5. Kosmas, C; Tsavaris, N; Panopoulos, C; Vadiaka, M; Stavroyianni, N; Kourelis, T; Malamos, N; Antonopoulos, M; Kalofonos, HP
      Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane plus platinum-based regimens

      EUROPEAN JOURNAL OF CANCER
    6. Laack, E; Mende, T; Benk, J; Chemaissani, A; Scholtze, J; Lorenz, C; Niestroy, A; Dalhoff, K; Muller, T; Walter, T; Durk, H; Edler, L; Hossfeld, DK
      Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial

      EUROPEAN JOURNAL OF CANCER
    7. Feliu, J; Martin, G; Lizon, J; Chacon, JI; Dorta, J; de Castro, J; Rodriguez, A; Heras, BS; Torrego, JC; Espinosa, E; Baron, MG
      Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study

      ANNALS OF ONCOLOGY
    8. Muller, H; Guadagni, S
      Regional plus systemic chemotherapy: an effective treatment in recurrent non-small cell lung cancer

      EUROPEAN JOURNAL OF SURGICAL ONCOLOGY
    9. Rinaldi, D; Lormand, N; Brierre, J; Cole, J; Barnes, B; Fontenot, F; Buller, E; Rainey, J
      A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3)

      CANCER INVESTIGATION
    10. von Pawel, J; Gatzemeier, U; Pujol, JL; Moreau, L; Bildat, S; Ranson, M; Richardson, G; Steppert, C; Riviere, A; Camlett, I; Lane, S; Ross, G
      Phase II comparator study of oral versus intravenous topotecan in patientswith chemosensitive small-cell lung cancer

      JOURNAL OF CLINICAL ONCOLOGY
    11. Goss, PE; Strasser, K
      Aromatase inhibitors in the treatment and prevention of breast cancer

      JOURNAL OF CLINICAL ONCOLOGY
    12. Locher, C; Auperin, A; Boige, V; Alzieu, L; Pignon, JP; Abbas, M; Ducreux, M
      Assessment of the cost of first line chemotherapy in metastatic colorectalcancer. Preliminary results in the FFCD 9601 trial

      GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
    13. Christian, J; Thomas, H
      Ovarian cancer chemotherapy

      CANCER TREATMENT REVIEWS
    14. Pectasides, D; Kalofonos, HP; Samantas, E; Nicolaides, C; Papacostas, P; Onyenadum, A; Visvikis, A; Skarlos, D; Fountzilas, G
      An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic Co-Operative Oncology Group

      ANTICANCER RESEARCH
    15. van Putten, JWG; Baas, P; Codrington, H; Kwa, HB; Muller, M; Aaronson, N; Groen, HJM
      Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer

      LUNG CANCER
    16. De Pas, T; de Braud, F; Mandala, M; Curigliano, G; Catania, C; Ferretti, G; Sozzi, P; Solli, P; Goldhirsch, A
      Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine

      LUNG CANCER
    17. Mariani, G; Tagliabue, P; Zucchinelli, P; Brambilla, C; Demicheli, R; Villa, E; Marchiano, A; Valagussa, P; Bonadonna, G; Gianni, L
      Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer

      BREAST CANCER RESEARCH AND TREATMENT
    18. Kakolyris, S; Kouroussis, C; Souglakos, J; Mavroudis, D; Agelaki, S; Kalbakis, K; Androulakis, N; Vardakis, N; Vamvakas, L; Georgoulias, V
      A phase I clinical trial of topotecan given every 2 weeks in patients withrefractory solid tumors

      ONCOLOGY
    19. Hainsworth, JD; Burris, HA; Billings, FT; Bradof, JE; Baker, M; Greco, FA
      Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma - Phase II trials of the Minnie Pearl Cancer Research Network

      CANCER
    20. Bajetta, E; Zilembo, N; Bichisao, E; Martinetti, A; Buzzoni, R; Pozzi, P; Bidoli, P; Ferrari, L; Celio, L
      Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors

      ANNALS OF ONCOLOGY
    21. Huisman, C; Smit, EF; Giaccone, G; Postmus, PE
      Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: A review

      JOURNAL OF CLINICAL ONCOLOGY
    22. de Jonge, MJA; Loos, WJ; Gelderblom, H; Planting, AST; van der Burg, MEL; Sparreboom, A; Brouwer, E; van Beurden, V; Mantel, MA; Doyle, E; Hearn, S; Ross, G; Verweij, J
      Phase I pharmacologic study of oral topotecan and intravenous cisplatin: Sequence-dependent hematologic side effects

      JOURNAL OF CLINICAL ONCOLOGY
    23. Wolf, M
      Topotecan in the first-line treatment of small-cell lung cancer

      ONKOLOGIE
    24. Rosati, G; Rossi, A; Nicolella, G; Panza, N
      Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer

      ANTICANCER RESEARCH
    25. Gridelli, C; Frontini, L; Barletta, E; Rossi, A; Barzelloni, ML; Scognamiglio, F; Guida, C; Gatani, T; Fiore, F; De Bellis, M; Marfella, A; Manzione, L
      Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A phase II study and review of the literature

      ANTICANCER RESEARCH
    26. Ferrigno, D; Buccheri, G
      Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?

      LUNG CANCER
    27. du Bois, A; Luck, HJ; Bauknecht, T; Pfisterer, J; Meier, W
      Second-line chemotherapie after platinum or platinum and paclitaxel-based chemotherapy for ovarian cancer: A systematic review

      GEBURTSHILFE UND FRAUENHEILKUNDE
    28. Ornstein, DL; Pipas, JM; Rigas, JR
      Recent advances in cancer chemotherapy

      ACADEMIC RADIOLOGY
    29. Pectasides, D; Aspropotamitis, A; Halikia, A; Visvikis, A; Antoniou, F; Kalantaridou, A; Karvounis, N; Batzios, S; Athanassiou, A
      Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: A phase II study

      JOURNAL OF CLINICAL ONCOLOGY
    30. Huisman, C; Postmus, PE; Giaccone, G; Smit, EF
      Second-line chemotherapy and its evaluation in small cell lung cancer

      CANCER TREATMENT REVIEWS
    31. Monnin, KA; Bronstein, IB; Gaffney, DK; Holden, JA
      Elevations of DNA topoisormerase I in transitional cell carcinoma of the urinary bladder: Correlation with DNA topoisomerase II-alpha and p53 expression

      HUMAN PATHOLOGY
    32. Kollmannsberger, C; Mross, K; Jakob, A; Kanz, L; Bokemeyer, C
      Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience

      ONCOLOGY
    33. Ormrod, D; Spencer, CM
      Topotecan - A review of its efficacy in small cell lung cancer

      DRUGS
    34. QUANTIN X; GODARD P; MICHEL FB; PUJOL JL
      NEW CYTOTOXICS IN THE TREATMENT OF ASTHMA AND BRONCHIAL-CANCER

      Revue des maladies respiratoires
    35. KELDSEN N; MADSEN EL; HAVSTEEN H; KAMBY C; LAURSEN L; SANDBERG E
      ORAL TREOSULFAN AS 2ND-LINE TREATMENT IN PLATINUM-RESISTANT OVARIAN-CANCER - A PHASE-II STUDY

      Gynecologic oncology
    36. BEZWODA WR; GUDGEON A; FALKSON G; JORDAAN JP; GOEDHALS L
      FADROZOLE VERSUS MEGESTROL-ACETATE - A DOUBLE-BLIND RANDOMIZED TRIAL IN ADVANCED BREAST-CANCER

      Oncology
    37. BLEIBERG H
      OXALIPLATIN (L-OHP) - A NEW REALITY IN COLORECTAL-CANCER

      British Journal of Cancer
    38. VANHALTEREN HK; WAGENER DJT; VREUGDENHIL G; PUNT CJA
      ADVANCED COLORECTAL-CANCER, REFRACTORY TO INFUSIONAL FLUOROURACIL TREATMENT - EFFICACY OF 2ND LINE FLUOROURACIL IN COMBINATION WITH A DIFFERENT BIOCHEMICAL MODULATION

      Anticancer research
    39. SWISHER EM; MUTCH DG; RADER JS; ELBENDARY A; HERZOG TJ
      TOPOTECAN IN PLATINUM-RESISTANT AND PACLITAXEL-RESISTANT OVARIAN-CANCER

      Gynecologic oncology
    40. LAUNOIS RJ; REBOULMARTY JM; BONNETERRE J
      A MEDICO-ECONOMIC ANALYSIS OF 2ND-LINE CH EMOTHERAPY IN METASTATIC BREAST-CANCER - DOCETAXEL VERSUS PACLITAXEL VERSUS VINORELBINE

      Bulletin du cancer
    41. GOLDBERG JM; PIVER MS; HEMPLING RE; RECIO FO
      PACLITAXEL AND CISPLATIN COMBINATION CHEMOTHERAPY IN RECURRENT EPITHELIAL OVARIAN-CANCER

      Gynecologic oncology
    42. TIRELLI U; ERRANTE D; SPINA M; GASTALDI R; NIGRA E; NOSARI AM; MAGNANI G; VACCHER E
      2ND-LINE CHEMOTHERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-RELATED NON-HODGKINS-LYMPHOMA - EVIDENCE OF ACTIVITY OF A COMBINATION OF ETOPOSIDE, MITOXANTRONE, AND PREDNIMUSTINE IN RELAPSED PATIENTS

      Cancer
    43. CHAUVERGNE J; CHINETCHARROT P; STOCKLE E; THOMAS L; TOULOUSE C
      CARBOPLATIN AND ETOPOSIDE COMBINATION FOR THE TREATMENT OF RECURRENT EPITHELIAL OVARIAN-CANCER

      Bulletin du cancer
    44. DILEO A; BAJETTA E; BIGANZOLI L; BOHM S; MARIANI L; MENARD S; PILOTTI S; FABBIANI M; GEBBIA V; ORIANA S; OTTONE F; RIBOLDI G; SAVA C; SPATTI G; ZUNINO F; DIRE F
      AN ITMO GROUP-STUDY ON 2ND-LINE TREATMENT IN ADVANCED EPITHELIAL OVARIAN-CANCER - AN ATTEMPT TO IDENTIFY CLINICAL AND BIOLOGICAL FACTORS DETERMINING PROGNOSIS

      European journal of cancer
    45. JAGER E; KLEIN O; WACHTER B; MULLER B; BRAUN U; KNUTH A
      2ND-LINE TREATMENT WITH HIGH-DOSE 5-FLUOROURACIL AND FOLINIC ACID IN ADVANCED COLORECTAL-CANCER REFRACTORY TO STANDARD-DOSE 5-FLUOROURACIL TREATMENT

      Oncology
    46. IAFFAIOLI RV; TORTORIELLO A; FACCHINI G; SANTANGELO M; DESENA G; GESUE G; BUCCI L; SCARAMELLINO G; ANASTASIO E; FINIZIO A; ANTONELLI B; VALLEFUOCO V; MOSELLA G; CAPONIGRO F
      A PHASE-II STUDY OF CARBOPLATIN AND VINORELBINE AS 2ND-LINE TREATMENTFOR ADVANCED BREAST-CANCER

      British Journal of Cancer
    47. BOLIS G; SCARFONE G; LUCHINI L; FERRARIS C; ZANABONI F; PRESTI M; GIARDINA G; VILLA A; PARAZZINI F
      RESPONSE TO 2ND-LINE WEEKLY CISPLATIN CHEMOTHERAPY IN OVARIAN-CANCER PREVIOUSLY TREATED WITH A CISPLATIN-BASED OR CARBOPLATIN-BASED REGIMEN

      European journal of cancer
    48. DILEO A; BIGANZOLI L; BOHM S; LUPI G; ORIANA S; RIBOLDI G; SPATTI G; VICARIO G; DIRE F; BAJETTA E
      AN INTENSIVE TREATMENT WITH MITOXANTRONE AND IFOSFAMIDE IN 2ND-LINE THERAPY OF EPITHELIAL OVARIAN-CANCER

      Tumori
    49. PYRHONEN S; VALAVAARA R; VUORINEN J; HAJBA A
      HIGH-DOSE TOREMIFENE IN ADVANCED BREAST-CANCER RESISTANT TO OR RELAPSED DURING TAMOXIFEN TREATMENT

      Breast cancer research and treatment
    50. CHRISTIAN MC; TRIMBLE EL
      SALVAGE CHEMOTHERAPY FOR EPITHELIAL OVARIAN-CARCINOMA

      Gynecologic oncology
    51. ALLEN DG; BAAK J; BELPOMME D; BEREK JS; BERTELSEN K; HUININK WWT; VANDERBURG MEL; CALVERT AH; CONTE PE; DAUPLAT J; EISENHAUER EA; FAVALLI G; HACKER NF; HAMILTON TC; HANSEN HH; HANSEN M; VANHOUWELINGEN HC; KAYE SB; LEVIN L; LUND B; NEIJT JP; OZOLS RF; PICCART MJ; RUSTIN GJS; SESSA C; SOUTTER WP; THIGPEN JT; TROPE C; VERMORKEN JB; DEVRIES EGE
      ADVANCED EPITHELIAL OVARIAN-CANCER - 1993 CONSENSUS STATEMENTS

      Annals of oncology
    52. TUMMARELLO D; GRAZIANO F; GIORDANI P; CELLERINO R
      FACTORS INFLUENCING RESPONSE TO 2ND-LINE TREATMENT WITH TENIPOSIDE (VM26) IN PATIENTS WITH PROGRESSIVE SMALL-CELL LUNG-CANCER (SCLC)

      Anticancer research
    53. SCHEITHAUER W; KORNEK G; HAIDER K; KWASNY W; SCHENK T; PIRKER R; DEPISCH D
      EFFECTIVE 2ND LINE CHEMOTHERAPY OF ADVANCED BREAST-CANCER WITH NAVELBINE AND MITOMYCIN-C

      Breast cancer research and treatment


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/05/20 alle ore 01:20:29